Iran's Operation Epic Fury Was a Sell-the-News Event for Defense Stocks — But the Trillion-Dollar Rearmament Aftermath Is Setting Up LMT, RTX, and NOC for Something Far Bigger
The biggest misconception in today's market is that war is inherently good for defense stocks. The Iran conflict — Operation Epic Fury, the largest U.S. military campaign since the 2003 Iraq invasion — proved otherwise. Defense equities actually underperformed the S&P 500 during the 39 days of active combat. But something far more consequential is now unfolding in the aftermath: a trillion-dollar rearmament cycle that could define defense sector returns for the next half-decade.
Here's why Wall Street is looking at the wrong chapter of this story — and where the real opportunity may be emerging.
★ Related Stocks & ETFs to Watch
| Ticker | Company / ETF | Sector | Iran/Rearmament Relevance | Signal |
|---|---|---|---|---|
| RTX | RTX Corporation | Defense – Missiles & Munitions | Tomahawk, SM-6, AMRAAM production surge; $5.36B cumulative contract framework | Bullish Catalyst |
| LMT | Lockheed Martin | Defense – Aerospace & Missiles | $4.76B PAC-3 MSE award; PrSM ramp from 152 to 550/yr; $186B backlog | Mixed — Execution Watch |
| NOC | Northrop Grumman | Defense – Strategic Systems | B-21 bomber, nuclear deterrence funding, solid rocket motor supplier | Bullish Catalyst |
| LHX | L3Harris Technologies | Defense – C4ISR & Munitions | Backlog nearly doubled to $40B+; 15% organic revenue growth Q1 2026 | Bullish Catalyst |
| GD | General Dynamics | Defense – Combat Systems & Marine | 2-to-1 book-to-bill ratio; shipbuilding allocation from One Big Beautiful Bill | Bullish Catalyst |
| HON | Honeywell Aerospace | Defense – Subsystems & Components | $500M multi-year capacity expansion; critical subsystem supplier for missile programs | Emerging Play |
| BA | Boeing | Aerospace & Defense | F-15EX, tanker programs; mixed defense/commercial exposure | Mixed |
| XOM | ExxonMobil | Energy – Integrated Oil | Beneficiary of post-Hormuz oil price volatility and refining spreads | Indirect Beneficiary |
| CVX | Chevron | Energy – Integrated Oil | Upstream production gains from elevated crude pricing | Indirect Beneficiary |
| COP | ConocoPhillips | Energy – E&P | Pure-play upstream leverage to geopolitical risk premium in crude | Indirect Beneficiary |
| ZIM | ZIM Integrated Shipping | Shipping – Container | Freight rate volatility from Middle East shipping rerouting | Elevated Volatility |
| ITA | iShares U.S. Aerospace & Defense ETF | ETF – Defense | Broad defense sector exposure; down ~12% from March highs | Pullback Watch |
| DFEN | Direxion Daily Aero & Defense Bull 3X | ETF – Leveraged Defense | 3x leveraged defense exposure; high-risk/high-reward on rearmament thesis | High Risk |
| XLE | Energy Select Sector SPDR | ETF – Energy | Broad energy exposure to Iran-driven oil supply disruption | Indirect Beneficiary |
| USO | United States Oil Fund | ETF – Crude Oil | Direct crude price exposure to Middle East tensions and supply risk | Contango Risk |
The Paradox: America Went to War — and Defense Stocks Fell
When U.S. and Israeli forces launched Operation Epic Fury against Iran on February 28, 2026, the reflexive assumption on trading desks was straightforward: defense stocks go up when America goes to war. For about 48 hours, that assumption held. LMT surged 7%, RTX jumped 5%, and NOC climbed nearly 6% in the opening days of the campaign.
Then something unexpected happened. They gave it all back — and then some.
The iShares U.S. Aerospace & Defense ETF (ITA) dropped approximately 12% from its early March peak through late April, even as the broader S&P 500 added 3.5% over the same period. The defense sub-index, which had already surged more than 150% between 2020 and 2025, found itself trading at roughly 32 times forward earnings — well above the S&P 500's multiple of about 20x. Valuations were stretched, and the war didn't provide the earnings catalyst Wall Street needed to justify them.
RTX tumbled more than 11% after its full-year sales guidance missed consensus. Lockheed Martin cratered 13% on a weak first quarter. Expectations for 2026 earnings growth across the Big Five defense contractors slipped from approximately 15% at the start of the year to about 12% by late March.
The lesson was brutal and clarifying: wars consume munitions, not quarterly earnings beats.
Why Active Combat Is Actually a Headwind for Defense Earnings
This counterintuitive dynamic deserves unpacking, because it's central to understanding what comes next.
During active hostilities, the Pentagon's spending priorities undergo a radical shift. Funds that would normally flow toward modernization programs, next-generation platforms, and long-term R&D contracts — the high-margin work that defense investors actually value — get diverted to immediate operational needs: fuel, logistics, personnel deployment, and munitions consumption from existing stockpiles.
The U.S. military struck more than 13,000 targets over 39 days during Operation Epic Fury. According to analysis from the Center for Strategic and International Studies (CSIS), the United States may have expended more than half its prewar inventory of at least four critical munition types, including Tomahawk cruise missiles. That's an extraordinary burn rate — but it was inventory that had already been manufactured and paid for. The revenue from those missiles was booked years ago.
In other words, the war depleted defense companies' past production without immediately generating new revenue. It created future demand at the expense of near-term earnings optics. And for a sector trading at 32x earnings, optics matter enormously.
The Market Got the Timeframe Wrong
What the market priced as a short-duration event — a few weeks of airstrikes, a ceasefire, move on — is in reality the opening act of a multi-year industrial mobilization. The ceasefire that ended active combat didn't end the investment thesis. It arguably started the real one.
The Rearmament Imperative: Years, Not Quarters
Restoring the munitions stockpiles burned through during Operation Epic Fury is not a matter of flipping a switch. It's an industrial challenge that will take years to execute — and the scope is staggering.
The Production Ramp Is Unprecedented
In early March, President Trump convened defense industry executives at the White House, where they reportedly committed to quadrupling production of what the administration calls "Exquisite Class Weaponry" — precision-guided systems like Tomahawk cruise missiles, Patriot interceptors, and SM-6 air defense missiles defined by their complexity, cost, and current scarcity.
The specific production targets announced are extraordinary:
- RTX/Raytheon: AMRAAM production ramping to over 1,900 units/year; SM-6 exceeding 500/year; Tomahawk reaching 1,000/year; accelerated SM-3 interceptor output. A $905 million production contract awarded April 16 contributes to an overall $5.36 billion cumulative framework.
- Lockheed Martin: PrSM (Precision Strike Missile) ramping from ~152 units/year to 550 units/year under a seven-year framework. A $4.76 billion PAC-3 MSE award was announced in early April. The company has committed $150 million to a new production facility in Troy, Alabama.
- Honeywell Aerospace: A $500 million multi-year framework to expand production of critical missile subsystems — addressing one of the least visible but most important bottlenecks in the supply chain.
But here's the critical constraint: historical manufacturing lead times for these systems run approximately 24 months. In recent years, as orders have outstripped capacity, those lead times have stretched to 36 months or more. Even with aggressive investment, restoring depleted stockpiles to pre-war levels — let alone achieving desired inventory targets — will take the better part of a decade.
That's not a trade. That's a cycle.
The Legislative Accelerant: A Trillion-Dollar Defense Budget Takes Shape
The rearmament imperative collided with an unusually receptive political environment, producing what may be the most consequential defense funding legislation since the Reagan-era buildup.
The One Big Beautiful Bill Act, signed into law after passing the Senate in a razor-thin 51-50 vote broken by Vice President JD Vance, allocated approximately $150 billion in mandatory defense funding on top of the Pentagon's $848 billion base budget request for FY2026. This pushes total planned defense spending above $1 trillion for the first time in U.S. history.
The allocation breakdown reveals where the money is flowing:
- $20.4 billion for munitions production — directly feeding the RTX, LMT, and GD order books
- $12.9 billion for nuclear deterrence — a core NOC revenue driver via the B-21 and Sentinel ICBM programs
- $7.2 billion for air superiority programs
- $13.5 billion for defense technology acceleration, including production-scaling for nontraditional defense companies
- Significant allocations for shipbuilding and the Golden Dome homeland missile defense initiative
Crucially, the Department of Defense has signaled its intention to spend the entire $152 billion within a single fiscal year, according to Federal News Network — creating a near-term procurement tsunami that will flow through contractor income statements starting in the back half of 2026 and accelerating through 2027.
This isn't speculative demand. These are signed framework agreements backed by appropriated funds with multi-year performance obligations. For defense investors, this is as close to guaranteed future revenue as public markets get.
Company-by-Company: Who's Best Positioned for the Rearmament Cycle?
RTX Corporation (RTX) — The Munitions Kingpin
If you had to pick one company at the center of America's post-Iran rearmament effort, it's RTX. The Raytheon division manufactures the Tomahawk, SM-6, SM-3, AMRAAM, and Stinger — essentially the full spectrum of precision munitions that were depleted during Operation Epic Fury.
Q1 2026 results validated the thesis: Raytheon-branded defense sales rose approximately 10% to $6.9 billion, driven by land and air defense demand. RTX raised full-year guidance after delivering 9% revenue growth and 21% adjusted EPS growth. The company also completed a missile facility expansion and signed landmark production framework agreements with the Pentagon.
RTX currently trades around $177, with a consensus Moderate Buy rating and a price target suggesting limited near-term upside. But most analyst models haven't fully incorporated the multi-year revenue duration from rearmament contracts that are still being negotiated. The company's unique positioning across every major depleted munition category makes it the most direct pure-play on the rearmament thesis.
Northrop Grumman (NOC) — The Strategic Deterrence Play
While RTX dominates tactical munitions, NOC occupies the strategic high ground. The B-21 Raider stealth bomber, the Sentinel ICBM replacement program, and the company's role as a critical solid rocket motor supplier position it uniquely within the rearmament cycle.
Q1 2026 was strong: sales rose 4% to $9.9 billion, with net earnings nearly doubling year-over-year to $875 million ($6.14/share vs. $3.32). The company reaffirmed full-year guidance across all major metrics. Notably, NOC's role as a solid rocket motor manufacturer addresses one of the most acute bottlenecks in the entire munitions supply chain — a constraint that multiple prime contractors are depending on NOC to resolve.
At approximately $556 per share, NOC carries a consensus Moderate Buy rating with an average price target of $541 — suggesting the stock is fairly valued or slightly ahead of consensus estimates. However, the $12.9 billion nuclear deterrence allocation in the One Big Beautiful Bill is a direct tailwind for NOC's highest-margin programs.
Lockheed Martin (LMT) — The Backlog Giant With Execution Questions
LMT presents the most complex picture. On one hand, the company sits atop a colossal $186 billion backlog — arguably the most formidable order book in the history of the defense industry. The $4.76 billion PAC-3 MSE award and the seven-year PrSM production ramp are exactly the kind of multi-year contracts that create revenue visibility.
On the other hand, Q1 2026 was disappointing. Revenue was essentially flat, and profits declined due to execution challenges in the Aeronautics and Rotary & Mission Systems segments. While management reaffirmed full-year guidance, the stock has fallen roughly 25% from its 2026 highs, leaving it at approximately $533 with a forward P/E of about 17.7x.
The bull case for LMT rests on the assumption that execution issues are temporary and the backlog conversion will accelerate. The bear case is that a $186 billion backlog means nothing if the company can't deliver on time and on budget. Analyst consensus is Hold, with a 12-month target around $627 — implying about 18% upside if the execution thesis plays out.
L3Harris (LHX) — The Dark Horse Outperformer
Perhaps the most underappreciated beneficiary of the Iran rearmament cycle is L3Harris Technologies. Q1 2026 was exceptional: revenue grew over $600 million, representing 15% organic growth. The company lifted its full-year profit forecast. Most strikingly, LHX's backlog nearly doubled to over $40 billion — and that figure doesn't yet include an estimated $25 billion in orders from the Pentagon's Munitions Acceleration Council programs currently under negotiation.
LHX's product mix — electronic warfare systems, ISR platforms, and munitions — aligns precisely with the lessons learned from Operation Epic Fury, where Iranian drone threats elevated demand for jamming and signal-disruption technologies. For investors seeking defense exposure beyond the traditional Big Three, LHX deserves serious consideration.
The Bottleneck Paradox: Why Constraints Could Extend Returns
Here's an element that most surface-level analyses miss: the production bottleneck is actually a feature, not a bug, for long-term defense investors.
The Pentagon's requested 188% increase in missile procurement spending vastly exceeds current industrial capacity. Solid rocket motors remain a critical chokepoint. Specialized alloys, advanced seekers, and guidance electronics all face supply constraints. RTX has had to collaborate with Anduril, Northrop Grumman, Avio USA, and Nammo to expand the solid rocket motor supply chain — a process measured in years, not quarters.
This means the rearmament revenue can't be front-loaded even if the Pentagon wanted to spend faster. Instead, it will flow steadily over a five-to-seven-year production ramp, creating the kind of durable, predictable revenue growth that defense investors haven't seen since the post-9/11 buildup. Framework agreements with companies like Lockheed and RTX are structured as multi-year commitments precisely because the industrial capacity doesn't yet exist to deliver faster.
For income-oriented investors, this dynamic transforms defense primes from volatile event-driven trades into something closer to infrastructure-grade cash flow generators — companies with contractually committed revenue streams extending well into the 2030s.
Broader Market Implications: Oil, Currencies, and Risk Premia
The Iran rearmament cycle doesn't exist in isolation. It intersects with broader market dynamics that investors should monitor:
Energy Markets
While the ceasefire has eased acute supply disruption fears, the geopolitical risk premium embedded in crude oil remains elevated. U.S. integrated majors like XOM and CVX continue to benefit from elevated refining margins and the structural repricing of Middle East supply risk. The rearmament effort itself consumes significant energy — jet fuel, industrial power, logistics — creating a secondary demand channel that often goes unnoticed.
The Crowding-Out Question
A trillion-dollar defense budget raises legitimate questions about fiscal sustainability and the potential for defense spending to crowd out other government priorities. Rising Treasury yields could compress defense stock multiples even as earnings grow — a scenario that could explain why the sector trades at a discount to the broader market on a growth-adjusted basis despite superior revenue visibility.
Allied Rearmament
The Iran conflict has accelerated defense spending commitments from allied nations across the Gulf Cooperation Council, NATO, and the Indo-Pacific. Foreign Military Sales (FMS) surged in Q1 2026, creating an additional demand channel for U.S. defense primes that is independent of the domestic budget cycle. This international dimension adds another layer of revenue durability to the thesis.
Investment Considerations: What to Watch From Here
For investors evaluating the post-Iran defense thesis, several key factors deserve close monitoring:
- Contract Award Cadence: The pace of new framework agreements and production contracts through the back half of 2026 will determine how quickly the One Big Beautiful Bill's $150 billion translates into booked orders and backlog growth. Watch quarterly 8-K filings from RTX, LMT, and NOC for award announcements.
- Margin Trajectory: Munitions production typically carries different margin profiles than platform development. As the revenue mix shifts toward high-volume munitions production, investors should watch whether operating margins expand (due to scale efficiencies) or compress (due to fixed-price contracts and input cost inflation).
- Capacity Milestones: Facility expansions at Lockheed's Troy plant, RTX's missile facilities, and Honeywell's subsystem operations will provide tangible proof points. Delays here would push revenue recognition further right — positive for duration, but potentially negative for near-term sentiment.
- Valuation Re-Rating: The ITA ETF's roughly 12% pullback from March highs may represent a healthier entry point, but the sector still trades at a premium to historical averages. The forward P/E compression in LMT (from ~25x trailing to ~17.7x forward) suggests the market is beginning to price in earnings growth — but hasn't fully credited the multi-year duration story.
- Geopolitical Escalation Risk: A breakdown of the ceasefire or escalation with Iranian proxies could reignite the operational spending diversion that hurt defense earnings during active combat. Paradoxically, renewed hostilities could be near-term bearish for the stocks even as they strengthen the long-term rearmament thesis.
The Bottom Line
The Iran war taught investors a lesson that sounds obvious in retrospect but was painful to learn in real time: wars deplete existing stockpiles; the rebuilding of those stockpiles is what creates investable revenue growth. The market spent February through April trading the headlines. The smarter positioning may be to trade the industrial response — a response that is backed by over $1 trillion in appropriated defense spending, multi-year framework agreements with mandated production ramps, and capacity bottlenecks that virtually guarantee a 5-7 year revenue duration.
RTX, NOC, LHX, and — if execution improves — LMT are the most direct expressions of this thesis. But the rearmament cycle's reach extends into subsystem suppliers like Honeywell, shipbuilders funded by the One Big Beautiful Bill, and international allies placing record Foreign Military Sales orders.
The ceasefire didn't end the defense trade. It may have simply marked the transition from Chapter One — the war nobody's stocks were priced for — to Chapter Two — the rearmament cycle that could define the sector for the rest of the decade.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always do your own research before making investment decisions. Past performance of defense stocks during prior conflicts is not indicative of future results. The geopolitical situation involving Iran remains fluid, and investment outcomes may differ materially from the scenarios discussed above.
댓글
댓글 쓰기